Ares Financial Consulting, LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 2106717
CALABASAS, CA
Position in HALO
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$12,053
+$2,100 QoQ
Shares Held
154
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#570
of 664 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ares Financial Consulting, LLC holds $306,023 across 44 Biotechnology names. HALO ranks #5 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
245 | $121,698 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
71 | $44,271 | |
| 3 | TECH |
BIO-TECHNE Corp
|
408 | $28,825 | |
| 4 | ARGX |
Argenx SE
|
26 | $24,122 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
This page
|
154 | $12,053 | |
| 6 | GMAB |
Genmab A/S
|
363 | $9,971 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
34 | $6,367 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
21 | $6,321 |
All Filings in HALO
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,053 | 154 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $9,953 | 154 | Shares | Sole | 2026-04-02 | |
| 2025-12-31 | $10,364 | 154 | Shares | Sole | 2026-01-30 | |
| No filing history on record for this holder in this stock. | ||||||